|
 The European Commission earlier this month approved the company's
antibody therapy Regkirona, granting marketing authorisation for
adults with COVID-19 who are at increased risk of progressing to a
severe condition.
The first batch of 50,000 doses will be shipped to Europe this year
and the company is in talks with 47 other nations including in Asia,
Central and South America and the Middle East, Celltrion said in a
statement.
The antibody treatment was initially approved in South Korea and has
been administered to around 25,000 local COVID-19 patients as of
last week.
[to top of second column] |
 Laboratory-made monoclonal antibodies mimic
natural antibodies in fighting off infections.
Unlike vaccines, they do not rely on the body to
create an immune response, and can therefore
help individuals with weak or compromised immune
systems.
(Reporting by Sangmi Cha; editing by Richard
Pullin)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
